New drug cocktail targets advanced cancers in early trial

NCT ID NCT01087554

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth and division. The study is active but no longer recruiting, and will also measure tumor response as a secondary goal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mTOR inhibitors (sirolimus, everolimus, temsirolimus) combined with vorinostat
What this could lead to: If successful, this could identify a tolerable drug combination that shrinks tumors or slows cancer growth in patients who have run out of standard options.
What could go wrong: This is an early Phase I trial focused on safety and dosing, not effectiveness. The combination may cause significant side effects or fail to control the cancer. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.